As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: ...

Startup Clairity scored a greenlight from the FDA for the agency's first artificial intelligence tool designed to predict ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Smiths Medical also identified three issues associated with the potential for thermal damage in affected infusion pumps. If ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...

Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Elon Musk's brain-computer interface startup Neuralink secured $650 million in series E funding to expand patient access to ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...